199 related articles for article (PubMed ID: 35176774)
1. Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
Uriu K; Cárdenas P; Muñoz E; Barragan V; Kosugi Y; Shirakawa K; Takaori-Kondo A; ; Sato K
J Infect Dis; 2022 Sep; 226(7):1200-1203. PubMed ID: 35176774
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
3. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
6. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.
Greaney AJ; Loes AN; Gentles LE; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
Sci Transl Med; 2021 Jun; 13(600):. PubMed ID: 34103407
[TBL] [Abstract][Full Text] [Related]
7. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
8. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
9. Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey.
Mathema B; Chen L; Wang P; Cunningham MH; Mediavilla JR; Chow KF; Luo Y; Zhao Y; Composto K; Zuckerman J; Zody MC; Wilson N; Lee A; Oschwald DM; Liu L; Iketani S; Germer S; Fennessey S; Wang M; Kramer Y; Toole P; Maniatis T; Ho DD; Perlin DS; Kreiswirth BN
mBio; 2022 Oct; 13(5):e0214122. PubMed ID: 35997285
[TBL] [Abstract][Full Text] [Related]
10. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
Fenwick C; Turelli P; Pellaton C; Farina A; Campos J; Raclot C; Pojer F; Cagno V; Nusslé SG; D'Acremont V; Fehr J; Puhan M; Pantaleo G; Trono D
Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34257144
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant.
Halfmann PJ; Kuroda M; Armbrust T; Theiler J; Balaram A; Moreno GK; Accola MA; Iwatsuki-Horimoto K; Valdez R; Stoneman E; Braun K; Yamayoshi S; Somsen E; Baczenas JJ; Mitamura K; Hagihara M; Adachi E; Koga M; McLaughlin M; Rehrauer W; Imai M; Yamamoto S; Tsutsumi T; Saito M; Friedrich TC; O'Connor SL; O'Connor DH; Gordon A; Korber B; Kawaoka Y
Sci Transl Med; 2022 Aug; 14(657):eabm4908. PubMed ID: 35579540
[TBL] [Abstract][Full Text] [Related]
12. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.
Teng IT; Nazzari AF; Choe M; Liu T; Oliveira de Souza M; Petrova Y; Tsybovsky Y; Wang S; Zhang B; Artamonov M; Madan B; Huang A; Lopez Acevedo SN; Pan X; Ruckwardt TJ; DeKosky BJ; Mascola JR; Misasi J; Sullivan NJ; Zhou T; Kwong PD
PLoS One; 2022; 17(5):e0268767. PubMed ID: 35609088
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
[TBL] [Abstract][Full Text] [Related]
15. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
[TBL] [Abstract][Full Text] [Related]
16. Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019.
Tang J; Grubbs G; Lee Y; Wu H; Luke TC; Egland KA; Bausch CL; Sullivan EJ; Khurana S
J Infect Dis; 2022 Sep; 226(4):655-663. PubMed ID: 35106573
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
Front Immunol; 2021; 12():751584. PubMed ID: 34630430
[TBL] [Abstract][Full Text] [Related]
18. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
19. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
Hein S; Herrlein ML; Mhedhbi I; Bender D; Haberger V; Benz N; Eisert J; Stingl J; Dreher M; Oberle D; Schulze J; Mache C; Budt M; Hildt C; Wolff T; Hildt E
Allergy; 2022 Jul; 77(7):2080-2089. PubMed ID: 34820854
[TBL] [Abstract][Full Text] [Related]
20. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
